SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Chemistry creative concept. Circle frame with icons. Flag of China
Manufacturing
Innovent’s CDMO gets green light to make biologics at large Chinese plant
The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial clients as it works to expand the plant’s capacity to 172,000 liters.
April 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Trendy halftone collage. Legislation concept, regulations, rules, law, authority, legal document, verdict. Hands holding a gavel with scales and regulation document. Vector illustration
FDA
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes.
April 7, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Vector illustration of a businessman unplugging polluted factory
Manufacturing
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Abstract financial chart with stock graph market.Vector illustration
Tariffs
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waive or greatly reduce the levies.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Hands protect to stop rectangle block dominos with others rectangle standing. Risk and crisis management concept.
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
April 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Novo Nordisk advertising flags and logo on facade
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
April 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pills, capsules and tablets that shape the map of the world, as a symbol for global medicine issues. Vector illustration.
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
April 1, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: Skyline of Atlanta
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
March 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Microscopes, books and test tubes amidst colorful balls on a pink background.-3d rendering."n
FDA
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of new approach methodologies, experts told BioSpace, particularly emphasizing the agency’s recommendations around defining NAMs’ regulatory purpose.
March 24, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Symbolic image: Tablets, US Dollar and China - Dependence on the Chinese pharmaceutical industry
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a business person giving a presentation in front of a board of directors, vector illustration
Business
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA.
March 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
Manufacturing
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in China.
March 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Photo of Philadelphia downtown city skyline
Manufacturing
TerraPower Commits $450M To Build Radioisotope Production Plant
Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.
March 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
Manufacturing
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.
March 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
change business management, businessman turn gear cog to manage change direction arrows, professional or expertise to manage company transformation or implement new process concept vector illustration
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Load More